



## Clinical trial results:

### A Phase II, Multicenter, Randomized Study To Compare The Efficacy Of Venetoclax

### Plus Fulvestrant Versus Fulvestrant In Women With Estrogen Receptor-Positive, HER2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy

#### Summary

EudraCT number	2017-005118-74
Trial protocol	GB DE
Global end of trial date	

#### Results information

Result version number	v1
This version publication date	05 August 2021
First version publication date	05 August 2021

#### Trial information

##### Trial identification

Sponsor protocol code	WO40181
-----------------------	---------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03584009
WHO universal trial number (UTN)	-

Notes:

##### Sponsors

Sponsor organisation name	F. Hoffmann-La Roche AG
Sponsor organisation address	Grenzacherstrasse 124, Basel, Switzerland, CH4070
Public contact	F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG, +41 616878333, global.trial_information@roche.com
Scientific contact	F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG, +41 616878333, global.trial_information@roche.com

Notes:

##### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Interim
Date of interim/final analysis	05 August 2020
Is this the analysis of the primary completion data?	Yes
Primary completion date	05 August 2020
Global end of trial reached?	No

Notes:

## General information about the trial

Main objective of the trial:

To evaluate and compare the efficacy of Venetoclax in combination with Fulvestrant versus Fulvestrant in Women with Estrogen Receptor-Positive, HER2-Negative locally advanced or Metastatic Breast Cancer

Protection of trial subjects:

All study subjects were required to sign an Informed Consent Form

Background therapy:

Subjects must not have received more than two prior lines of hormonal therapy in the locally advanced or metastatic setting. In addition, at least one line of treatment must be a CDK4/6i AND subjects must have experienced disease recurrence or progression during or after CDK4/6i therapy, which must have been administered for a minimum of 8 weeks prior to progression.

Evidence for comparator: -

Actual start date of recruitment	06 September 2018
Long term follow-up planned	Yes
Long term follow-up rationale	Efficacy
Long term follow-up duration	2 Years
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Australia: 23
Country: Number of subjects enrolled	Canada: 24
Country: Number of subjects enrolled	Germany: 14
Country: Number of subjects enrolled	United Kingdom: 13
Country: Number of subjects enrolled	United States: 29
Worldwide total number of subjects	103
EEA total number of subjects	14

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0

Adolescents (12-17 years)	0
Adults (18-64 years)	72
From 65 to 84 years	30
85 years and over	1

## Subject disposition

### Recruitment

Recruitment details:

The study was conducted at 38 centers in 5 countries.

### Pre-assignment

Screening details:

A total of 103 subjects were randomized in this study. Of these, 101 subjects received at least one dose of any study drug.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Venetoclax + Fulvestrant

Arm description:

Subjects were administered Venetoclax 800mg orally once daily (QD) and Fulvestrant 500mg intramuscularly (IM) on Day 1 and 15 of Cycle 1 and Day 1 of subsequent cycles (Cycle length = 28 days).

Arm type	Experimental
Investigational medicinal product name	Venetoclax
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Venetoclax was administered orally once daily (QD) at a dose of 800mg.

Investigational medicinal product name	Fulvestrant
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Fulvestrant was administered intramuscularly (IM) at a dose of 500mg (on Day 1 and 15 of Cycle 1 and Day 1 of subsequent cycles (Cycle length = 28 days).

<b>Arm title</b>	Fulvestrant
------------------	-------------

Arm description:

Subjects were administered Fulvestrant 500mg only intramuscularly (IM) on Day 1 and 15 of Cycle 1 and Day 1 of subsequent cycles (Cycle length = 28 days).

Arm type	Active comparator
Investigational medicinal product name	Fulvestrant
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Fulvestrant was administered intramuscularly (IM) at a dose of 500mg (on Day 1 and 15 of Cycle 1 and Day 1 of subsequent cycles (Cycle length = 28 days).

<b>Number of subjects in period 1</b>	<b>Venetoclax + Fulvestrant</b>	<b>Fulvestrant</b>
Started	51	52
Completed	0	0
Not completed	51	52
Physician decision	1	1
Consent withdrawn by subject	3	1
Ongoing in study	29	40
Death	18	9
Lost to follow-up	-	1

## Baseline characteristics

### Reporting groups

Reporting group title	Venetoclax + Fulvestrant
Reporting group description:	
Subjects were administered Venetoclax 800mg orally once daily (QD) and Fulvestrant 500mg intramuscularly (IM) on Day 1 and 15 of Cycle 1 and Day 1 of subsequent cycles (Cycle length = 28 days).	
Reporting group title	Fulvestrant
Reporting group description:	
Subjects were administered Fulvestrant 500mg only intramuscularly (IM) on Day 1 and 15 of Cycle 1 and Day 1 of subsequent cycles (Cycle length = 28 days).	

Reporting group values	Venetoclax + Fulvestrant	Fulvestrant	Total
Number of subjects	51	52	103
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	38	34	72
From 65-84 years	12	18	30
85 years and over	1	0	1
Age Continuous Units: years			
arithmetic mean	57.4	58.8	-
standard deviation	± 10.6	± 11.7	-
Sex: Female, Male Units: Participants			
Female	51	52	103
Male	0	0	0
Race/Ethnicity, Customized Units: Subjects			
Hispanic or Latino	1	3	4
Not Hispanic or Latino	47	46	93
Not Reported	3	3	6
Race/Ethnicity, Customized Units: Subjects			
Asian	6	3	9
Black or African American	3	2	5
White	40	46	86
Multiple	1	0	1
Unknown	1	1	2

## End points

### End points reporting groups

Reporting group title	Venetoclax + Fulvestrant
Reporting group description: Subjects were administered Venetoclax 800mg orally once daily (QD) and Fulvestrant 500mg intramuscularly (IM) on Day 1 and 15 of Cycle 1 and Day 1 of subsequent cycles (Cycle length = 28 days).	
Reporting group title	Fulvestrant
Reporting group description: Subjects were administered Fulvestrant 500mg only intramuscularly (IM) on Day 1 and 15 of Cycle 1 and Day 1 of subsequent cycles (Cycle length = 28 days).	

### Primary: Clinical benefit defined as Complete Response (CR), Partial Response (PR) or Stable Disease (SD) lasting $\geq 24$ weeks, as determined by the Investigator according to RECIST v1.1

End point title	Clinical benefit defined as Complete Response (CR), Partial Response (PR) or Stable Disease (SD) lasting $\geq 24$ weeks, as determined by the Investigator according to RECIST v1.1
End point description: Clinical Benefit was defined as Complete Response, Partial Response, or Stable Disease lasting more than equal to 24 weeks from randomization in subjects with measurable disease at baseline, as determined by the investigator according to Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v1.1. Per RECIST v1.1 for target lesions assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), $\geq 30\%$ decrease in the sum of the diameters of target lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for Disease Progression (PD), taking as reference the smallest sum on study.	
End point type	Primary
End point timeframe: Randomization through till 6 months after the last subject is enrolled into the study.	

End point values	Venetoclax + Fulvestrant	Fulvestrant		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	51	51		
Units: Percentage of Subjects				
number (confidence interval 95%)	11.8 (4.44 to 23.87)	13.7 (5.70 to 26.26)		

### Statistical analyses

Statistical analysis title	(Venetoclax + Fulvestrant) vs Fulvestrant
Comparison groups	Venetoclax + Fulvestrant v Fulvestrant

Number of subjects included in analysis	102
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.7286 <sup>[1]</sup>
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	-1.96
Confidence interval	
level	95 %
sides	2-sided
lower limit	-16.86
upper limit	12.94

Notes:

[1] - P-value is based on Stratified Analysis (Stratified by BCL2 status (High vs Low) and Lines of Therapy (2 vs 1)).

## Secondary: Progression Free Survival (PFS)

End point title	Progression Free Survival (PFS)
End point description:	
PFS was defined as the time from randomization to the first occurrence of disease progression (as determined by the investigator according to RECIST v1.1) or death from any cause, whichever occurs first.	
End point type	Secondary
End point timeframe:	
Randomization through till 6 months after the last subject is enrolled into the study.	

End point values	Venetoclax + Fulvestrant	Fulvestrant		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	51	52		
Units: Months				
median (confidence interval 95%)	2.69 (1.94 to 3.71)	1.94 (1.84 to 3.55)		

## Statistical analyses

<b>Statistical analysis title</b>	(Venetoclax + Fulvestrant) vs Fulvestrant
Comparison groups	Venetoclax + Fulvestrant v Fulvestrant
Number of subjects included in analysis	103
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.7853 <sup>[2]</sup>
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	0.94



Confidence interval	
level	95 %
sides	2-sided
lower limit	0.61
upper limit	1.45

Notes:

[2] - P-value is based on Stratified Analysis (Stratified by BCL2 status (High vs Low) and Lines of Therapy (2 vs 1)).

## Secondary: Objective Response (OR)

End point title	Objective Response (OR)
-----------------	-------------------------

End point description:

OR was defined as Complete Response (CR) or Partial response (PR), in subjects with measurable disease at baseline as determined by the investigator according to RECIST v1.1.

End point type	Secondary
----------------	-----------

End point timeframe:

Randomization through till 6 months after the last subject is enrolled into the study.

End point values	Venetoclax + Fulvestrant	Fulvestrant		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	51	51		
Units: Percentage of Subjects				
number (confidence interval 95%)	3.9 (0.48 to 13.46)	5.9 (1.23 to 16.24)		

## Statistical analyses

<b>Statistical analysis title</b>	(Venetoclax + Fulvestrant) vs Fulvestrant
Comparison groups	Venetoclax + Fulvestrant v Fulvestrant
Number of subjects included in analysis	102
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5978 <sup>[3]</sup>
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	-1.96
Confidence interval	
level	95 %
sides	2-sided
lower limit	-12.29
upper limit	8.37

Notes:

[3] - P-value is based on Stratified Analysis (Stratified by BCL2 status (High vs Low) and Lines of Therapy (2 vs 1)).

## Secondary: Duration of Response (DOR)

End point title	Duration of Response (DOR)
-----------------	----------------------------

End point description:

DOR was defined as the time from the first occurrence of a documented objective response to the time of the first documented disease progression (as determined by the investigator according to RECIST v1.1) or death from any cause, whichever occurs first. 9999 = Not Estimable.

End point type	Secondary
----------------	-----------

End point timeframe:

Time from first occurrence of a documented objective response to the time of the first documented disease progression or death from any cause, whichever occurs first, until 6 months after the last subject is enrolled into the study.

End point values	Venetoclax + Fulvestrant	Fulvestrant		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2	3		
Units: Months				
median (confidence interval 95%)	9999 (9999 to 9999)	3.61 (1.94 to 9999)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of Subjects with Adverse Events (AEs)

End point title	Percentage of Subjects with Adverse Events (AEs)
-----------------	--

End point description:

An Adverse Event (AE) is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An Adverse Event can therefore be any unfavorable and unintended sign (including abnormal laboratory values or abnormal clinical test results), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as Adverse Events. Data collection is still ongoing and the results will be disclosed within 1 year from the Study Completion Date.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline up until 28 days after the last dose of study drug (venetoclax or fulvestrant, whichever is later).

End point values	Venetoclax + Fulvestrant	Fulvestrant		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 <sup>[4]</sup>	0 <sup>[5]</sup>		
Units: Percentage of Subjects				

Notes:

[4] - Data for this Endpoint will only be reported within 1 year from the Final Study Completion Date.

[5] - Data for this Endpoint will only be reported within 1 year from the Final Study Completion Date.

## Statistical analyses

No statistical analyses for this end point

## Secondary: Overall Survival (OS)

End point title	Overall Survival (OS)
-----------------	-----------------------

End point description:

Overall Survival (OS) is defined as the time from randomization to death due to any cause. Data collection is still ongoing and the results will be disclosed within 1 year from the Study Completion Date.

End point type	Secondary
----------------	-----------

End point timeframe:

Randomization to death from any cause, through till the end of the study (2 years after the last subject is enrolled)

End point values	Venetoclax + Fulvestrant	Fulvestrant		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 <sup>[6]</sup>	0 <sup>[7]</sup>		
Units: Months				
median (confidence interval 95%)	( to )	( to )		

Notes:

[6] - Data for this Endpoint will only be reported within 1 year from the Final Study Completion Date.

[7] - Data for this Endpoint will only be reported within 1 year from the Final Study Completion Date.

## Statistical analyses

No statistical analyses for this end point

## Secondary: Plasma Concentrations of Venetoclax at specified timepoints

End point title	Plasma Concentrations of Venetoclax at specified timepoints
-----------------	---

End point description:

The PK analyses includes tabulation of plasma concentration data and summarisation of plasma concentrations by visits with subjects grouped according to treatment received. Descriptive summary statistics for the Arithmetic Mean and Standard Deviation are presented below. Data collection is still ongoing and the results will be disclosed within 1 year from the Study Completion Date.

End point type	Secondary
----------------	-----------

End point timeframe:

At pre-defined intervals from Cycle 1, Day 1, through till the end of treatment (2 years after the last subject is enrolled).

End point values	Venetoclax + Fulvestrant	Fulvestrant		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 <sup>[8]</sup>	0 <sup>[9]</sup>		
Units: µg/mL				
arithmetic mean (standard deviation)	( )	( )		

Notes:

[8] - Data for this Endpoint will only be reported within 1 year from the Final Study Completion Date.

[9] - Data for this Endpoint will only be reported within 1 year from the Final Study Completion Date.

## Statistical analyses

No statistical analyses for this end point

### Secondary: Plasma Concentrations of Fulvestrant at specified timepoints

End point title	Plasma Concentrations of Fulvestrant at specified timepoints
-----------------	--

End point description:

The PK analyses includes tabulation of plasma concentration data and summarisation of plasma concentrations by visits with subjects grouped according to treatment received. Descriptive summary statistics for the Arithmetic Mean and Standard Deviation are presented below. Data collection is still ongoing and the results will be disclosed within 1 year from the Study Completion Date.

End point type	Secondary
----------------	-----------

End point timeframe:

At pre-defined intervals from Cycle 1, Day 1, through till the end of treatment (2 years after the last subject is enrolled).

End point values	Venetoclax + Fulvestrant	Fulvestrant		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 <sup>[10]</sup>	0 <sup>[11]</sup>		
Units: µg/mL				
arithmetic mean (standard deviation)	( )	( )		

Notes:

[10] - Data for this Endpoint will only be reported within 1 year from the Final Study Completion Date.

[11] - Data for this Endpoint will only be reported within 1 year from the Final Study Completion Date.

## Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Baseline up until 28 days after the last dose of study drug (venetoclax or fulvestrant, whichever is later).

Adverse event reporting additional description:

The 1 additional death in the Ven + Fulv arm compared to in the Subject Disposition section, relates to a subject who had withdrawn consent from the study and later died. Their death was reported in public records.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
Dictionary version	23.0

### Reporting groups

Reporting group title	Venetoclax + Fulvestrant
-----------------------	--------------------------

Reporting group description:

Subjects were administered Venetoclax 800mg orally once daily (QD) and Fulvestrant 500mg intramuscularly (IM) on Day 1 and 15 of Cycle 1 and Day 1 of subsequent cycles (Cycle length = 28 days).

Reporting group title	Fulvestrant
-----------------------	-------------

Reporting group description:

Subjects were administered Fulvestrant 500mg only intramuscularly (IM) on Day 1 and 15 of Cycle 1 and Day 1 of subsequent cycles (Cycle length = 28 days).

Serious adverse events	Venetoclax + Fulvestrant	Fulvestrant	
Total subjects affected by serious adverse events			
subjects affected / exposed	4 / 50 (8.00%)	1 / 51 (1.96%)	
number of deaths (all causes)	19	9	
number of deaths resulting from adverse events			
Investigations			
Ejection fraction decreased			
subjects affected / exposed	1 / 50 (2.00%)	0 / 51 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	1 / 50 (2.00%)	0 / 51 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			

Pleural effusion			
subjects affected / exposed	0 / 50 (0.00%)	1 / 51 (1.96%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Flank pain			
subjects affected / exposed	0 / 50 (0.00%)	1 / 51 (1.96%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Lower respiratory tract infection			
subjects affected / exposed	1 / 50 (2.00%)	0 / 51 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urosepsis			
subjects affected / exposed	1 / 50 (2.00%)	0 / 51 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Venetoclax + Fulvestrant	Fulvestrant	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	45 / 50 (90.00%)	34 / 51 (66.67%)	
Vascular disorders			
Hot flush			
subjects affected / exposed	1 / 50 (2.00%)	9 / 51 (17.65%)	
occurrences (all)	1	9	
General disorders and administration site conditions			
Chest pain			
subjects affected / exposed	4 / 50 (8.00%)	0 / 51 (0.00%)	
occurrences (all)	4	0	
Fatigue			
subjects affected / exposed	18 / 50 (36.00%)	8 / 51 (15.69%)	
occurrences (all)	20	8	

Injection site pain subjects affected / exposed occurrences (all)	0 / 50 (0.00%) 0	9 / 51 (17.65%) 12	
Injection site reaction subjects affected / exposed occurrences (all)	6 / 50 (12.00%) 7	6 / 51 (11.76%) 7	
Oedema peripheral subjects affected / exposed occurrences (all)	4 / 50 (8.00%) 6	1 / 51 (1.96%) 1	
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all)	8 / 50 (16.00%) 9	4 / 51 (7.84%) 4	
Dyspnoea subjects affected / exposed occurrences (all)	5 / 50 (10.00%) 5	3 / 51 (5.88%) 3	
Psychiatric disorders Insomnia subjects affected / exposed occurrences (all)	8 / 50 (16.00%) 8	4 / 51 (7.84%) 4	
Investigations Alanine aminotransferase increased subjects affected / exposed occurrences (all)	3 / 50 (6.00%) 3	4 / 51 (7.84%) 4	
Aspartate aminotransferase increased subjects affected / exposed occurrences (all)	4 / 50 (8.00%) 4	3 / 51 (5.88%) 3	
Blood alkaline phosphatase increased subjects affected / exposed occurrences (all)	2 / 50 (4.00%) 2	4 / 51 (7.84%) 4	
Blood creatine phosphokinase increased subjects affected / exposed occurrences (all)	4 / 50 (8.00%) 4	2 / 51 (3.92%) 2	
Weight decreased			

subjects affected / exposed occurrences (all)	3 / 50 (6.00%) 3	0 / 51 (0.00%) 0	
Injury, poisoning and procedural complications Injection related reaction subjects affected / exposed occurrences (all)	5 / 50 (10.00%) 9	4 / 51 (7.84%) 4	
Nervous system disorders Dizziness subjects affected / exposed occurrences (all)  Headache subjects affected / exposed occurrences (all)	5 / 50 (10.00%) 5  7 / 50 (14.00%) 8	2 / 51 (3.92%) 2  8 / 51 (15.69%) 8	
Blood and lymphatic system disorders Anaemia subjects affected / exposed occurrences (all)  Leukopenia subjects affected / exposed occurrences (all)  Lymphopenia subjects affected / exposed occurrences (all)  Neutropenia subjects affected / exposed occurrences (all)	2 / 50 (4.00%) 2  3 / 50 (6.00%) 3  7 / 50 (14.00%) 7  8 / 50 (16.00%) 11	3 / 51 (5.88%) 3  1 / 51 (1.96%) 1  0 / 51 (0.00%) 0  0 / 51 (0.00%) 0	
Gastrointestinal disorders Abdominal distension subjects affected / exposed occurrences (all)  Abdominal pain subjects affected / exposed occurrences (all)  Abdominal pain upper subjects affected / exposed occurrences (all)	5 / 50 (10.00%) 5  4 / 50 (8.00%) 4  4 / 50 (8.00%) 4	1 / 51 (1.96%) 1  0 / 51 (0.00%) 0  1 / 51 (1.96%) 1	



Constipation			
subjects affected / exposed	8 / 50 (16.00%)	2 / 51 (3.92%)	
occurrences (all)	8	2	
Diarrhoea			
subjects affected / exposed	27 / 50 (54.00%)	5 / 51 (9.80%)	
occurrences (all)	37	6	
Dry mouth			
subjects affected / exposed	4 / 50 (8.00%)	0 / 51 (0.00%)	
occurrences (all)	4	0	
Nausea			
subjects affected / exposed	32 / 50 (64.00%)	9 / 51 (17.65%)	
occurrences (all)	40	10	
Vomiting			
subjects affected / exposed	15 / 50 (30.00%)	1 / 51 (1.96%)	
occurrences (all)	23	1	
Hepatobiliary disorders			
Hepatic pain			
subjects affected / exposed	3 / 50 (6.00%)	0 / 51 (0.00%)	
occurrences (all)	3	0	
Skin and subcutaneous tissue disorders			
Pruritus			
subjects affected / exposed	4 / 50 (8.00%)	1 / 51 (1.96%)	
occurrences (all)	5	1	
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	5 / 50 (10.00%)	6 / 51 (11.76%)	
occurrences (all)	5	8	
Back pain			
subjects affected / exposed	3 / 50 (6.00%)	5 / 51 (9.80%)	
occurrences (all)	3	6	
Musculoskeletal chest pain			
subjects affected / exposed	1 / 50 (2.00%)	8 / 51 (15.69%)	
occurrences (all)	2	9	
Pain in extremity			
subjects affected / exposed	4 / 50 (8.00%)	1 / 51 (1.96%)	
occurrences (all)	4	2	

Infections and infestations Upper respiratory tract infection subjects affected / exposed occurrences (all)	3 / 50 (6.00%) 3	1 / 51 (1.96%) 1	
Metabolism and nutrition disorders Decreased appetite subjects affected / exposed occurrences (all)	9 / 50 (18.00%) 9	2 / 51 (3.92%) 2	

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
19 September 2018	Primarily to provide clarifications and to ensure consistency across sections.

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

Primary and secondary efficacy endpoints have been updated to report 95% confidence interval (CI) for Clinical Benefit estimate and 95% CI for the Cox proportional hazards model for PFS, following reporting conventions.
---

Notes: